Literature DB >> 17826039

External beam radiotherapy and high dose rate brachytherapy for medically unfit and elderly patients.

C A M Marijnen1.   

Abstract

In the treatment of rectal cancer, total mesorectal excision surgery is now the standard of care. In most patients, surgery will be preceeded by radiotherapy, either in a short course (25 Gy/five fractions) or in a conventional schedule (45-50 Gy/25 fractions) with chemotherapy. For patients unfit for surgery or unwilling to undergo a procedure resulting in a permanent colostomy, radiotherapy without surgery is the alternative. From published studies it is clear that for relatively small tumours, local treatment with either contact X-rays or intraluminal brachytherapy is a reasonable option. For patients with larger tumours, the risk of nodal involvement makes the combination of local radiotherapy with external beam radiotherapy necessary. So far, this combination has mainly been given with contact X-rays and only sporadically with intraluminal brachytherapy. In this overview, a summary of published studies will be given, with a proposal for a trial for medically unfit patients with T2-T4 tumours.

Entities:  

Mesh:

Year:  2007        PMID: 17826039     DOI: 10.1016/j.clon.2007.07.015

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  3 in total

1.  High-dose-rate intraluminal brachytherapy during preoperative chemoradiation for locally advanced rectal cancers.

Authors:  Mutahir Ali Tunio; Mansoor Rafi; Altaf Hashmi; Rehan Mohsin; Abdul Qayyum; Mujahid Hasan; Amjad Sattar; Muhammad Mubarak
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

2.  Accomplishments in 2007 in the adjuvant treatment of rectal cancer.

Authors:  Lisa A Kachnic; Robert Glynne-Jones
Journal:  Gastrointest Cancer Res       Date:  2008-05

Review 3.  Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer.

Authors:  Valentina Lancellotta; György Kovács; Luca Tagliaferri; Elisabetta Perrucci; Giuseppe Colloca; Vincenzo Valentini; Cynthia Aristei
Journal:  Biomed Res Int       Date:  2018-01-21       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.